|
楼主 |
发表于 2008-11-20 14:32:32
|
显示全部楼层
119-6-第六节 硫哩漂吟的用法及注意事项
硫哩嚓吟的有效剂量为1. 5 -2 . 5mg/(kg "d)。在<1 mg/(kg " d )的剂量无治疗作用。在类风湿关节炎治疗中,本品可单用或与慢作用抗风湿药合用。但是,硫哇嗦吟单独应用对类风湿关节炎的治疗效果并不优于D一青霉胺或金制剂。其不良反应发生率与常用的慢作用抗风湿药类似。因此,硫噢嗦吟可能是类风湿关节炎联合治疗中可供选择的药物之一。 8 W% E! W8 f5 X3 J1 d* e
2 ^1 {1 R+ c. X4 f
一般而言,硫哇嚷吟第一周起始剂量为50mg/d。如能耐受,剂量可增加至2 . 5mg/(kg.d)。如以体重60kg计,每日剂量为0. 18g.用药前4周,应每2周检查血象和肝功能。如正常,以后改为每月检查一次。如果白细胞计数降至3.0 x 109/L以下,必需停药。白细胞在(3.0 4.0) x 109/L之间,则需提高监测频度,并考虑减量。减量后如血象恢复,以后也最好应用较小的剂量。减量或停药后,恶心和其他胃肠道反应常会随之好转。如有过敏反应,以后不应再考虑用硫哇嗓吟治疗。, B5 F1 O: w2 b0 c5 ?! R
- \* s$ F$ b" F( c L9 S
在合并别嚷醇治疗的患者,剂量应减少至1/4-1/3。在肾功能不全的患者也应根据肌醉清除率减少用药剂量。应尽量避免同时使用ACEI类药物治疗。
0 d, b% }+ e1 s: G; [- T2 v# m. L$ l9 I9 v$ D
孕妇最好不用本药治疗。但目前虽有导致染色体畸变和胎儿发育迟滞的报道,还未肯定其在人类有致畸作用。对必需硫噢嗦吟治疗的患者,妊娠过程中,不必强求一定停药。
* T1 E% ~ p1 q; \& ?1 @2 ? ( 穆 荣 )( D2 S5 ^1 [/ |- V
参考文献:
* f1 r6 h) N% L3 V% r# Z1 P, T9 B& i+ B
施桂英.关节炎概要.北京:中国医药科技出版社,2000.550 William J. Koopman. Arthritis and allied condition. USA.2000.794一814 , B: {! g1 f7 _1 p" ]
3 m5 c. w% ^) B Calin A. A placebo controlled, crossover study of azathio-prine in Reiter's syndrome. Ann Rheum Dis,1986-45(8):653一655 7 v4 |! H) ~7 V) Y* k" @& q
: E; m; M; |9 y4 `7 W9 B& W2 S: i E.Choy, G. Kingsley. How do second-line agents work?British Medical Bulletin, 1995.51(2) :472一492
% _7 z5 q) x" H+ c' Q- n7 @, A
6 Z2 E0 j7 {6 |$ D! @6 a K. Gaffney, D. G. 1. Scott. Azathioprine and cyclophos-phamide in the treatment of rheumatoid arthritis. Bri J Rheuma-tology,1998.37:824一836 6 v* Z& p" b$ e/ x
: V, }! ?- |# [/ L' @
Kerstens PJ, Stolk JN, Boerbooms AM, et. al. Purine en-zymes in rheumatoid arthritis. Ann Rheum Dis,1994. 53: 608一611
3 h) ? \9 Z: B& O7 v9 _7 b* J: V5 l5 Q$ j7 K9 F9 z
Kerstens PJ, Boerbooms AM, Jeurissen ME, et al. Radio-logical and clinical results of longterm treatment of rheumatoidarthritis with methotrexate and azathioprine. J Rheumato1,200027(5):1148一1155 ' m* W5 g! f/ X
1 Q4 w" ^! f' m- W) J$ p2 `+ b
Papadopoulos NG, Alamanos Y, Papadopoulos IA et al.Disease modifying antirheumatic drugs in early rheumatoid arthritis: a long term observational study. J Rheumatol, 2002. 29 ( 2 ):261一266
+ `- J4 H$ B. O% x0 Q, _# ?
& r5 i- Q! M& j( x1 h Ricardo B, Victor M M T, Miguel A G G, et al. Acutefebrile toxic reaction with refractory rheumatoid arthritis who arereceiving combined therapy with MTX and AZA. ArthritisRheum, 1996. 39:1016一1020
. E0 g0 g6 [; d/ ?8 L
7 T$ @: P& ]- K Rosalind R G, Ellen S. Immunosupressive drug use duringpregnancy. Rheum dis clin north Am. 1997. 23:149一167
9 ~5 q3 @' }" W9 L( g+ y7 g4 c& L ?/ P2 A8 k
Willkens RF, Sharp JT, Stablein D, et al. Comparison ofazathioprine, methotrexate, and the combination of the two inthe treatment of rheumatoid arthritis. A forty-eight-week con-trolled clinical trial with radiologic outcome assessment. ArthritisRheum, 1996.39(8):1436一1437 |
|